PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor. [electronic resource]
Producer: 20140312Description: e827 p. digitalISSN:- 2041-4889
- Apoptosis -- drug effects
- Cell Line, Tumor
- Cell Survival -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- Drug Screening Assays, Antitumor
- Fusion Proteins, bcr-abl -- metabolism
- Hematopoietic Stem Cells -- drug effects
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- pathology
- Models, Biological
- Neoplastic Stem Cells -- pathology
- Phosphatidylinositol 3-Kinases -- metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Phosphorylation -- drug effects
- Phosphotyrosine -- metabolism
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Pyrimidines -- pharmacology
- Signal Transduction -- drug effects
- Stem Cell Factor -- pharmacology
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.